T-cell childhood acute lymphocytic leukemia

Summary

T-cell childhood acute lymphocytic leukemia (MONDO:0000871) is a cancer and 43 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, cyclophosphamide anhydrous, and pegaspargase. A subtype of immune system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 43

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	T-cell childhood acute lymphocytic leukemia
Mondo ID	MONDO:0000871
EFO	EFO:1001947
DOID	DOID:0080145
NCIT	C7953
UMLS	C0279583
MedGen	75996
GARD	0007346
Is cancer (heuristic)	yes

Also known as: childhood precursor T-lymphoblastic leukaemia · childhood precursor T-lymphoblastic leukemia · childhood T acute lymphoblastic leukaemia · childhood T acute lymphoblastic leukemia · childhood T-ALL · childhood T-cell acute lymphoblastic leukaemia · childhood T-cell acute lymphoblastic leukemia · T acute lymphoblastic leukaemia · T acute lymphoblastic leukemia · T-cell childhood acute lymphoblastic leukaemia · T-cell childhood acute lymphoblastic leukemia · T-cell childhood acute lymphocytic leukemia · T-cell childhood ALL · T-cell paediatric acute lymphoblastic leukaemia · T-cell paediatric acute lymphocytic leukaemia · T-cell paediatric ALL · T-cell pediatric acute lymphoblastic leukemia · T-cell pediatric acute lymphocytic leukemia · T-cell pediatric ALL

Data availability: 658 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › T-cell childhood acute lymphocytic leukemia

Related subtypes (24): lymphatic system cancer, B-cell childhood acute lymphoblastic leukemia, primary central nervous system lymphoma, thymus cancer, solitary plasmacytoma of chest wall, dendritic cell sarcoma, Waldeyer’s ring cancer, breast diffuse large B-cell lymphoma, colon Burkitt lymphoma, colorectal diffuse large B-cell lymphoma, gastric mantle cell lymphoma, liver diffuse large B-cell lymphoma, primary pulmonary diffuse large B-cell lymphoma, small intestinal Burkitt lymphoma, small intestinal diffuse large B-cell lymphoma, small intestinal enteropathy-associated T-cell lymphoma, thyroid gland diffuse large B-cell lymphoma, plasma cell myeloma, indolent primary cutaneous B-cell lymphoma, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, mast cell sarcoma, subcutaneous panniculitis-like T-cell lymphoma, bone marrow cancer, primary vitreoretinal large b-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 43.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	13
PHASE1/PHASE2	8
PHASE1	7
PHASE3	6
Not specified	6
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02112916	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT03007147	PHASE3	ACTIVE_NOT_RECRUITING	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT05602194	PHASE3	ACTIVE_NOT_RECRUITING	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT07072585	PHASE2/PHASE3	NOT_YET_RECRUITING	Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
NCT00382109	PHASE3	COMPLETED	Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
NCT00408005	PHASE3	COMPLETED	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00557193	PHASE3	COMPLETED	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00501826	PHASE2	RECRUITING	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT03504644	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
NCT04128501	PHASE2	ACTIVE_NOT_RECRUITING	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT04315324	PHASE1/PHASE2	RECRUITING	Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06420076	PHASE1/PHASE2	RECRUITING	Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
NCT06738368	PHASE2	RECRUITING	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
NCT07012447	PHASE2	RECRUITING	Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
NCT07021677	PHASE2	RECRUITING	Use of a New Medicine Daratumumab to Treat Left-over Cancer in a Blood Cancer Called T Acute Lymphoblastic Leukemia
NCT00002970	PHASE2	COMPLETED	506U78 in Treating Patients With Refractory Hematologic Cancer
NCT00052520	PHASE1/PHASE2	COMPLETED	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
NCT00061945	PHASE1/PHASE2	COMPLETED	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00873093	PHASE2	COMPLETED	Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT01093586	PHASE2	COMPLETED	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02484430	PHASE2	COMPLETED	Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
NCT02538926	PHASE2	WITHDRAWN	Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT02763384	PHASE2	TERMINATED	BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
NCT02767934	PHASE2	TERMINATED	Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
NCT03808610	PHASE1/PHASE2	TERMINATED	Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
NCT05032183	PHASE1/PHASE2	TERMINATED	Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT05320380	PHASE1/PHASE2	WITHDRAWN	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
NCT06210750	PHASE2	WITHDRAWN	Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT00101205	PHASE1	TERMINATED	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT01088763	PHASE1	TERMINATED	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
NCT01403415	PHASE1	COMPLETED	Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
NCT03519984	PHASE1	TERMINATED	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
NCT04681105	PHASE1	COMPLETED	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NCT05127135	PHASE1	UNKNOWN	Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
NCT05519527	PHASE1	WITHDRAWN	STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
NCT06633354	EARLY_PHASE1	RECRUITING	Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
NCT07476027	EARLY_PHASE1	NOT_YET_RECRUITING	Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
NCT00016302	Not specified	COMPLETED	Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00049569	Not specified	COMPLETED	Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00437060	Not specified	COMPLETED	Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MERCAPTOPURINE ANHYDROUS	4	19
CYCLOPHOSPHAMIDE ANHYDROUS	4	15
PEGASPARGASE	4	9
NELARABINE	4	8
DAUNORUBICIN	4	6
THIOGUANINE	4	6
ASPARAGINASE	4	5
CALASPARGASE PEGOL	4	4
IMATINIB	4	4
DEXRAZOXANE	4	3
HYDROCORTISONE SODIUM SUCCINATE	4	2
IFOSFAMIDE	4	2
LEUCOVORIN	4	2
VINCRISTINE	4	2
ALEMTUZUMAB	4	1
BORTEZOMIB	4	1
DARATUMUMAB	4	1
HYDROCORTISONE	4	1
LEVOCARNITINE	4	1
LEVOLEUCOVORIN	4	1
SIROLIMUS	4	1
THIOTEPA	4	1
CARNITINE	3	1
LESTAURTINIB	3	1
CHEMBL4469622	0	1
DEXTROCARNITINE	0	1